BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)

A 4-Period, Placebo-Controlled, Crossover Study to Evaluate the Utility and Feasibility of BOLD fMRI and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (Donepezil and MK3134)

This study will evaluate functional magnetic resonance imaging (fMRI) and methods for measuring drug induced changes in cerebral blood flow as biomarkers for attention-improving drugs.

Inclusion Criteria:

• Subject is a nonsmoker
• Subject is in generally good health
• Subject has normal (or corrected to normal) vision and hearing
• Subject is right-handed

Exclusion Criteria:

• Subject has a history of any illness that would make participation unsafe or would make the study results difficult to interpret
• Subject has a history of stroke, seizures, or major neurological disorders
• Subject has a history of cancer
• Subject has permanent cosmetic or metallic implants that would interfere with measurements
• Subject has a history of sleep apnea
• Subject has a history of head injury/trauma